About 16 results found for searched term "Ro 51" (0.051 seconds)
Cat.No. | Name | Target |
---|---|---|
M1726 | FG-4592 (Roxadustat) | HIF |
Roxadustat; ASP1517 | ||
FG-4592 (Roxadustat; ASP1517) is a novel Hypoxia Inducible Factor Prolyl Hydroxylase inhibitor. | ||
M1761 | Vemurafenib (PLX4032) | Raf |
RG7204; RO5185426 | ||
Vemurafenib (PLX4032) is a first-in-class, potent, selective inhibitor of B-Raf that inhibits RAFV600E and C-RAF-1 activity with IC50s of 31 nM and 48 nM, respectively.In addition, Vemurafenib induces autophagy. | ||
M6245 | Basmisanil | GABA Receptor |
RG1662; RO5186582 | ||
Basmisanil is a highly selective GABAAα5 negative allosteric modulator. | ||
M7205 | Ro 15-4513 | Others |
Ro 15-4513 is a benzodiazepine partial inverse agonist. | ||
M7209 | Ro 51 | P2 Receptor |
Ro 51 is a potent P2X 3, P2X 2/3 antagonist. | ||
M10369 | RO5126766 (VS-6766) | MEK |
CH5126766; VS 6766; Avutometinib | ||
RO5126766 (CH5126766, VS 6766) is a first-in-class dual MEK/RAF inhibitor with IC50 values of 8.2 nM, 19 nM, 56 nM and 160 nM for BRAF V600E, BRAF, CRAF and MEK1, respectively. | ||
M10726 | ORY-1001 (trans) | Histone demethylase |
ORY-1001 dihydrochloride; RG6016 dihydrochloride; RO 7051790 dihydrochloride | ||
Dihydrochloride, Iadademstat (ORY-1001) is an irreversible inhibitor of selective Lysine-specific demethylase 1A (KDM1A/LSD1). | ||
M14642 | 2'-Deoxycytidine hydrochloride | Metabolite/Endogenous Metabolite |
2'-Deoxycytidine monohydrochloride; Deoxycytidine hydrochloride; NSC 83251 | ||
2'-Deoxycytidine hydrochloride is composed of the purine nucleoside guanine linked by its N9 nitrogen to the C1 carbon of deoxyribose. | ||
M14893 | PND-1186 hydrochloride | FAK |
VS-4718 hydrochloride; SR-2516 hydrochloride | ||
PND-1186 hydrochloride (VS-4718 hydrochloride) is a potent, highly-specific and reversible inhibitor of FAK with an IC50 of 1.5 nM. PND-1186 hydrochloride selectively promotes tumor cell apoptosis. | ||
M14901 | Tandutinib hydrochloride | FLT3 |
MLN518 hydrochloride; CT53518 hydrochloride | ||
Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. | ||
M21513 | Vemurafenib-d7 | Raf |
PLX4032-d7; RG7204-d7; RO5185426-d7 | ||
Vemurafenib (PLX4032; RG7204; RO5185426) is a first-in-class selective B-RAF inhibitor that inhibits the activity of RAFV600E and c-RAF-1 with IC50 at 31 nM and 48 nM, respectively. Vemurafenib can induce autophagy. | ||
M24630 | Codrituzumab | Others |
GC33 RO5137382 | ||
Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth. | ||
M27714 | RO5166017 | TAAR |
RO5166017 is an orally active and species-crosses TAAR1 agonist, with Ki values of 1.9 nM, 2.7 nM, 31 nM and 24 nM for mouse, rat, human and cynomolgus monkey, respectively. | ||
M40535 | LIP1 (human) | Peptides |
Prepro-β-NGF (51-79) (human) | ||
LIP1 (human) is a polypeptide produced from the anterior region of nerve growth factor (NGF) containing 29 amino acids that induces F-actin rearrangement, phosphorylates TrkA and Akt, and has antiproliferative as well as neuroprotective activities. Sequence: ARSAPAAAIAARVAGQTRNITVDPRLFKK | ||
M49404 | Butenoic acid | Others |
(E)-2-Butenoic acid; (E)-Crotonic acid; trans-2-Butenoic acid; trans-Crotonic acid; NSC 8751 | ||
Butenoic acid is an unsaturated fatty acid with a double bond and a carboxyl group in the molecule, which can be used in the synthesis of a variety of substances such as DL-Threonine and Vitamin A. | ||
M51325 | Agouti-Related Protein (25-51) (human) | Others |
Agouti-Related Protein (25-51) (human) (AGRP (25-51) (human)) is an amino-terminal 25-51 fragment of agouti-related protein (AGRP). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.